AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00507-08v1
52/12/4213    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Schurek, K. N.
Right arrow Articles by Hancock, R. E. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schurek, K. N.
Right arrow Articles by Hancock, R. E. W.

Next Article 

Antimicrobial Agents and Chemotherapy, December 2008, p. 4213-4219, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00507-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Novel Genetic Determinants of Low-Level Aminoglycoside Resistance in Pseudomonas aeruginosa{triangledown}

Kristen N. Schurek, Alexandra K. Marr, Patrick K. Taylor, Irith Wiegand, Lucie Semenec, Bhavjinder K. Khaira, and Robert E. W. Hancock*

Centre for Microbial Diseases and Immunity Research, University of British Columbia, 2259 Lower Mall, Vancouver, BC, Canada

Received 17 April 2008/ Returned for modification 23 May 2008/ Accepted 17 September 2008

Pseudomonas aeruginosa strains isolated from patients with persistent lung infections and cystic fibrosis have been found to gradually develop aminoglycoside resistance over time. The aim of this study was to identify potential contributors to low-level aminoglycoside resistance, which may cause such graduated increases in resistance. The Harvard P. aeruginosa PA14 nonredundant library, consisting of approximately 5,800 mutants, was screened for twofold or greater increases in tobramycin resistance. Mutants carrying mutations in a total of 135 unique genes were identified and confirmed to have reduced susceptibility to tobramycin. Many of these genes were involved predominantly in energy metabolism; however, most of these mutants did not exhibit growth defects under the conditions tested, although some exhibited the small-colony phenotype and/or defects in growth under anaerobic conditions. Lipopolysaccharide mutants were also identified, and it was found that tobramycin had a reduced ability to permeabilize the outer membranes of these mutants. The results of this study emphasize the complexity of the interactions that tobramycin may have within the bacterial cell and introduce a large number of novel genes which may play a role in tobramycin resistance.

* Corresponding author. Mailing address: Centre for Microbial Diseases and Immunity Research, University of British Columbia, Room 232, 2259 Lower Mall, Lower Mall Research Station, Vancouver, British Columbia V6T 1Z4, Canada. Phone: (604) 822-2682. Fax: (604) 827-5566. E-mail: bob{at}cmdr.ubc.ca

{triangledown} Published ahead of print on 29 September 2008.

Antimicrobial Agents and Chemotherapy, December 2008, p. 4213-4219, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00507-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.